top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjcardiovascrec

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood ...

Cardiovascular Research, Original Article, Tony Hayek, Judith Attias, Raymond Coleman, Sergey Brodsky, Jonathan Smith, Jan L. Breslow, Shlomo Keidar

Date : 01/12/1999
Ehjcardiovascrec

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood ...

Cardiovascular Research, Hayek, Tony, Attias, Judith, Coleman, Raymond, Brodsky, Sergey, Smith, Jonathan, Breslow, Jan L., Keidar, Shlomo

Date : 01/12/1999 Item size : 347527 bytes
Ehjcardiovascrec

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood ...

Cardiovascular Research, Hayek, Tony, Attias, Judith, Coleman, Raymond, Brodsky, Sergey, Smith, Jonathan, Breslow, Jan L., Keidar, Shlomo

Date : 01/12/1999
Ehjournal

The 2018 European Society of Cardiology-European Society of Hypertension (ESC-ESH) guidelines for the management of arterial hypertension1 lowered the blood pressure (BP) targets to <130/80mmHg, as ...

European Heart Journal, Vidal-Petiot, Emmanuelle, Elbez, Yedid, Lüscher, Thomas F, Fox, Kim M, Steg, Philippe Gabriel

Date : 01/12/2018 Item size : 121978 bytes